115 related articles for article (PubMed ID: 22292948)
1. Molecular dynamics of HIV1-integrase in complex with 93del - a structural perspective on the mechanism of inhibition.
Sgobba M; Olubiyi O; Ke S; Haider S
J Biomol Struct Dyn; 2012; 29(5):863-77. PubMed ID: 22292948
[TBL] [Abstract][Full Text] [Related]
2. DNA aptamers as potential anti-HIV agents.
Chou SH; Chin KH; Wang AH
Trends Biochem Sci; 2005 May; 30(5):231-4. PubMed ID: 15896739
[TBL] [Abstract][Full Text] [Related]
3. Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via molecular docking and comparative molecular dynamics simulation methods.
Hu JP; He HQ; Tang DY; Sun GF; Zhang YQ; Fan J; Chang S
J Biomol Struct Dyn; 2013; 31(7):734-47. PubMed ID: 22913375
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of an HIV-1 integrase aptamer: Formation of a water-mediated A•G•G•G•G pentad in an interlocked G-quadruplex.
Ngo KH; Liew CW; Lattmann S; Winnerdy FR; Phan AT
Biochem Biophys Res Commun; 2022 Jul; 613():153-158. PubMed ID: 35561583
[TBL] [Abstract][Full Text] [Related]
5. The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration.
Faure-Perraud A; Métifiot M; Reigadas S; Recordon-Pinson P; Parissi V; Ventura M; Andréola ML
Antivir Ther; 2011; 16(3):383-94. PubMed ID: 21555821
[TBL] [Abstract][Full Text] [Related]
6. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
7. Insight into the inhibitory mechanism and binding mode between D77 and HIV-1 integrase by molecular modeling methods.
Li P; Tan JJ; Liu M; Zhang XY; Chen WZ; Wang CX
J Biomol Struct Dyn; 2011 Oct; 29(2):311-23. PubMed ID: 21875151
[TBL] [Abstract][Full Text] [Related]
8. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
[TBL] [Abstract][Full Text] [Related]
10. Insight into the fundamental interactions between LEDGF binding site inhibitors and integrase combining docking and molecular dynamics simulations.
De Luca L; Morreale F; Chimirri A
J Chem Inf Model; 2012 Dec; 52(12):3245-54. PubMed ID: 23194297
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulations of the HIV-1 integrase dimerization interface: guidelines for the design of a novel class of integrase inhibitors.
Sippel M; Sotriffer CA
J Chem Inf Model; 2010 Apr; 50(4):604-14. PubMed ID: 20230013
[TBL] [Abstract][Full Text] [Related]
12. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
13. HIV integrase as a target for antiviral chemotherapy.
Nair V
Rev Med Virol; 2002; 12(3):179-93. PubMed ID: 11987143
[TBL] [Abstract][Full Text] [Related]
14. An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase.
Phan AT; Kuryavyi V; Ma JB; Faure A; Andréola ML; Patel DJ
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):634-9. PubMed ID: 15637158
[TBL] [Abstract][Full Text] [Related]
15. Binding modes of two novel dinucleotide inhibitors of HIV-1 integrase.
Guenther S; Nair V
Bioorg Med Chem Lett; 2002 Aug; 12(16):2233-6. PubMed ID: 12127545
[TBL] [Abstract][Full Text] [Related]
16. Improvement of the activity of the anti-HIV-1 integrase aptamer T30175 by introducing a modified thymidine into the loops.
Virgilio A; Amato T; Petraccone L; Esposito F; Grandi N; Tramontano E; Romero R; Haider S; Gomez-Monterrey I; Novellino E; Mayol L; Esposito V; Galeone A
Sci Rep; 2018 May; 8(1):7447. PubMed ID: 29749406
[TBL] [Abstract][Full Text] [Related]
17. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
18. Exploring the binding of d(GGGT)4 to the HIV-1 integrase: An approach to investigate G-quadruplex aptamer/target protein interactions.
Esposito V; Pirone L; Mayol L; Pedone E; Virgilio A; Galeone A
Biochimie; 2016 Aug; 127():19-22. PubMed ID: 27109379
[TBL] [Abstract][Full Text] [Related]
19. Structural studies and biological evaluation of T30695 variants modified with single chiral glycerol-T reveal the importance of LEDGF/p75 for the aptamer anti-HIV-integrase activities.
Rivieccio E; Tartaglione L; Esposito V; Dell'Aversano C; Koneru PC; Scuotto M; Virgilio A; Mayol L; Kvaratskhelia M; Varra M
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):351-361. PubMed ID: 30414444
[TBL] [Abstract][Full Text] [Related]
20. New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
Ferro S; De Luca L; Barreca ML; De Grazia S; Christ F; Debyser Z; Chimirri A
Bioorg Med Chem; 2010 Aug; 18(15):5510-8. PubMed ID: 20630765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
